Paras Healthcare Q2 FY27: Revenue Surges 22.8% YoY to ₹510.9 Cr, PAT Jumps 3.3x
Paras Healthcare reported Q2 FY27 revenue of ₹510.9 Crs, up 22.8% YoY. PAT surged 3.3x to ₹40.4 Crs. For H1 FY27, revenue grew 25.1% to ₹981.2 Crs, with PAT rising to ₹90.0 Crs. The company targets 3,011 beds by 2028 and recently listed on stock exchanges.
The announcement includes strong financial performance with substantial revenue and profit growth, a clear expansion strategy, and details about a recent successful IPO, all of which are material information for investors and indicate a high impact.
The company reported strong year-on-year growth in revenue, operating EBITDA, and a significant increase in Profit After Tax for both the quarter and half-year ended September 30, 2026. Positive outlook on future bed capacity expansion and recent successful IPO also contribute to the positive sentiment.
Paras Healthcare Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a significant year-on-year growth in revenue for the second quarter of FY27, reaching ₹510.9 Crs, an increase of 22.8% from ₹416.1 Crs in Q2 FY26. Operating EBITDA (excluding other income) saw a substantial rise of 47.0% to ₹120.2 Crs from ₹81.7 Crs in the prior year period. Profit After Tax (PAT) witnessed a remarkable jump of 3.3 times, growing from ₹12.4 Crs to ₹40.4 Crs.
Reported EBITDA (including other income) increased by 42.5% YoY to ₹126.6 Crs, with margins expanding by 350 basis points to 24.5%. The PAT margin also saw a significant improvement, growing by 490 basis points to 7.8%.
For the half-year ended September 30, 2026 (H1 FY27), Paras Healthcare reported a revenue of ₹981.2 Crs, up 25.1% YoY from ₹784.5 Crs in H1 FY26. Operating EBITDA grew by 58.4% to ₹225.2 Crs, and PAT surged by 7.9 times to ₹90.0 Crs from ₹11.4 Crs in the previous year.
The company highlighted its growth across hospital cohorts, with newer hospitals showing significant ramp-up in occupancy and EBITDA margins. Paras Healthcare is targeting 3,011 beds by 2028 across its network of 8 operational hospitals and 2 upcoming facilities in 6 states and 1 Union Territory.
The investor presentation also detailed the company's financial ratios, operating KPIs, specialty and payor mix, and strategic roadmap for sustained, profitable growth. Key initiatives include scaling up capacity in core markets, expanding the North India network, developing high-end clinical programs, attracting and retaining clinicians, and improving operational efficiencies.
The company was listed on the NSE and BSE on October 28, 2026, with an offer size of ₹1,450 Crs. The proceeds are intended for term debt repayment and general corporate purposes. The presentation also noted a CRISIL upgrade of the long-term rating to 'A-' from 'BBB+'.
What to do with a filing like this
Paras Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Paras Healthcare Limited. Read the original for the full detail.